Get access to our best features
Get access to our best features
Published 1 year ago

Pfizer's hemophilia B gene therapy succeeds in late-stage study

Summary by Ground News
Pfizer's investigational gene therapy for hemophilia B, fidanacogene elaparvovec, met the primary endpoint in a Phase 3 trial. The trial involved adults males with a moderately severe to severe form of the disease. Pfizer plans to disclose additional key data from the study at a scientific conference in early 2023.

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 50% of the sources are Center
49% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics